Oxytocin vs HCG
Head-to-head comparison of Oxytocin and HCG for research applications. Both peptides are studied for Reproductive Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Oxytocin | Hcg |
|---|---|---|
| Category | Reproductive / Hormonal | Hormonal / Reproductive |
| Mechanism | Oxytocin binds to the oxytocin receptor (OXTR), a Gq/11-coupled GPCR expressed in uterine myometrium, mammary tissue, and the central nervous system. | HCG binds to the LH/CG receptor (LHCGR) on Leydig cells and theca cells with high affinity. In males, this stimulates intratesticular testosterone production, spermatogenesis, and maintains testicular volume. |
| Evidence Rating | A — Approved Medication with Strong Human Data | A — FDA Approved |
| Clinical Status | FDA-approved (Pitocin for labor induction, augmentation of labor, and postpartum hemorrhage) | FDA-approved for anovulation/infertility, hypogonadotropic hypogonadism, prepubertal cryptorchidism. |
| Safety Profile | Uterine hyperstimulation/tachysystole: can cause excessive contractions leading to fetal distress; requires continuous fetal monitoring; Water intoxication and hyponatremia: oxytocin has antidiuretic properties at high doses; risk increases with prolonged infusion and hypotonic IV fluids | Common: injection site reactions, headache, fatigue, mood changes; Males: gynecomastia (from estradiol conversion), water retention, testicular discomfort |
| Route | Intravenous infusion (labor); Intramuscular injection (PPH); Intranasal spray (research) | Subcutaneous injection |
| Dose Range | Labor induction: 0.5-2 mU/min initial, titrated up to 20-40 mU/min; PPH prophylaxis: 10 IU IM; Intranasal (research): 24 IU | 250-500 IU per injection (750-1500 IU/week) |
| Frequency | Continuous IV infusion for labor; single IM dose for PPH prophylaxis | 3 times per week |
| Molecular Weight | ~1007.2 g/mol | ~36,700 g/mol (glycoprotein) |
| Half-Life | ~1-6 minutes (IV) | ~24-36 hours |
Overview
Oxytocin and HCG are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Oxytocin — Mechanism & Evidence
Oxytocin is an endogenous cyclic nonapeptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 with a disulfide bridge between Cys1 and Cys6, MW ~1007.2 g/mol) produced in the hypothalamus and released from the posterior pituitary. It acts on oxytocin receptors in the uterine myometrium to stimulate rhythmic contractions and on mammary myoepithelial cells to facilitate milk ejection.
Key claims: Induces and augments labor effectively; Prevents and treats postpartum hemorrhage; Facilitates milk ejection (let-down reflex).
HCG — Mechanism & Evidence
Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone (MW ~36,700 g/mol) composed of an alpha subunit (shared with LH, FSH, TSH) and a unique beta subunit. Naturally produced by placental trophoblasts during pregnancy, pharmaceutical HCG binds LH/CG receptors in the gonads, stimulating testosterone production in Leydig cells and progesterone in the corpus luteum. It is FDA-approved for multiple reproductive indications and is widely used off-label to maintain testicular function during testosterone replacement therapy (TRT).
Key claims: Maintains testicular function during TRT; Preserves fertility during testosterone use; Triggers ovulation in fertility treatment.
Shared Research Applications
Both peptides are studied for: Reproductive Health.
Oxytocin is also researched for: no additional unique applications.
HCG is also researched for: Hormonal.
Safety Considerations
Oxytocin: Uterine hyperstimulation/tachysystole: can cause excessive contractions leading to fetal distress; requires continuous fetal monitoring Water intoxication and hyponatremia: oxytocin has antidiuretic properties at high doses; risk increases with prolonged infusion and hypotonic IV fluids Uterine rupture: rare but life-threatening, especially in patients with prior uterine surgery
HCG: Common: injection site reactions, headache, fatigue, mood changes Males: gynecomastia (from estradiol conversion), water retention, testicular discomfort Females: ovarian hyperstimulation syndrome (OHSS) — potentially serious
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Gonadorelin vs HCG: Comparing GnRH Analogues in Reproductive Research
Compare gonadorelin vs HCG in reproductive research. Mechanisms, preclinical evidence, and limitations for GnRH analogue studies.
Oxytocin's Vital Role in Social and Relationship Bonds
Oxytocin, known as the love hormone, supports social connections through release during touch, trust, and intimacy. Research indicates it aids trust, empathy, and bonding in romantic, parental, and friendly relationships, though effects depend on context and individual factors. This peptide also interacts with stress systems to promote emotional regulation and well-being.
Atosiban Serves as Maintenance Therapy for Preterm Labor
Atosiban, an oxytocin-receptor antagonist marketed in China in 2006, offers maintenance treatment to manage preterm labor risks after initial tocolysis. Clinical trials show it delays delivery better than placebo in some cases and has fewer side effects than beta-2 agonists. Studies highlight its safety and role in reducing recurrent preterm labor episodes.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe